For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), who discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities.
Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally, with artificial intelligence, automation, and new robotic platforms remaining central to the company’s long-term product roadmap. Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely.
The SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating expenses. By focusing on affordability, the company aims to penetrate underserved markets and increase the volume of procedures performed globally.
The telesurgery capability is particularly significant, as it enables experienced surgeons to guide or perform procedures remotely, potentially bridging gaps in surgical expertise in remote or resource-limited settings. This technology could also reduce the need for patient travel and allow for more efficient use of specialist skills.
SS Innovations’ progress is reflected in its installed base and procedure volume, which provide real-world evidence of the system’s utility. The company’s regulatory strategy includes seeking clearance from the U.S. Food and Drug Administration and European regulatory bodies, which would open large markets and potentially drive further adoption.
Investors should note that while the company emphasizes its competitive differentiators, forward-looking statements in the release are subject to risks and uncertainties detailed in the company’s filings with the SEC. For a full understanding of the potential risks, refer to the “Risk Factors” section in SS Innovations’ most recent Annual Report on Form 10-K and subsequent quarterly reports.
For more information on the company’s vision and the interview, the full terms of use and disclaimers are available on the InvestorBrandNetwork website.
